Manganese oxide nanoparticles (Mn3O4 NPs) were synthesized and modified with an LHRH-targeting peptide or anti-melanoma antibodies (cancer-targeting moieties), as well as an MMP2 cleavable peptide (a possible chemotactic agent). Nanostructured lipid carriers (NLCs) were employed to entrap the BRAF inhibitor vemurafenib and enhance the drug’s cytotoxicity.
2025
Predictive Tool for Melanoma Could Guide Immunotherapy Choices
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
New Discovery on Protein Interaction and Proliferation of Melanoma
Melanoma that proliferates from pigment-producing melanocytes is the deadliest form of skin cancer, which can be caused by extensive ultraviolet light exposure, especially in individuals with low levels of melanin. A
NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma
NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.